Skip to content

PHARMADVICE: what changed

BE 0896.586.737Other company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
-€12,238
2024 · -€24,642+€12,404
Equity
€1.2m
2024 · €1.2m-€12,238
Cash
€172,593
2024 · €182,674-€10,082
Balance sheet total
€1.2m
2024 · €1.2m-€11,228

Largest movements

2024 to 2025
Assets
  • Tangible fixed assets -€31,737

    down €31,737 (-3.0%), from €1.1m to €1.0m

  • Current investments +€29,911

    first reported in 2025, at €29,911

Equity and liabilities

No liability line moved by more than 1% of the balance sheet total.

    Income statement
    • Gross operating margin +€12,323

      up €12,323 (+103%), from €11,928 to €24,251

    • Financial income +€317

      up €317 (+103%), from €308 to €625

    Change in the result, 2024 to 2025

    effect on the result

    For each income-statement line you see the change as its effect on the result. Higher costs lower the result, higher income raises it.

    Result 2024 -€24,642
    Gross operating margin +€12,323
    Other operating charges -€149
    Financial income +€317
    Financial charges -€87
    Result 2025 -€12,238
    raises the resultlowers the result

    Derived cash bridge

    cash 2024 to 2025

    The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

    From operations +€19,829
    Investment -€29,911
    Financing €0
    Cash 2024 €182,674
    Net result for the year -€12,238
    Depreciation +€31,737
    Receivables within one year -€680
    Trade debts +€431
    Other debts +€331
    Accrued charges and deferred income +€248
    Current investments -€29,911
    Cash 2025 €172,593
    brings cash intakes cash out
    Every line side by side 35 lines
    Line Code 2024 2025 Change %
    Total assets 20/58 €1,236,022 €1,224,794 -€11,228 -0.9%
    Fixed assets 21/28 €1,050,109 €1,018,372 -€31,737 -3.0%
    Tangible fixed assets 22/27 €1,050,109 €1,018,372 -€31,737 -3.0%
    Land and buildings 22 €1,050,109 €1,018,372 -€31,737 -3.0%
    Current assets 29/58 €185,913 €206,422 +€20,509 +11.0%
    Amounts receivable within one year 40/41 €3,238 €3,918 +€680 +21.0%
    Other amounts receivable 41 €3,238 €3,918 +€680 +21.0%
    Current investments 50/53 - €29,911 +€29,911
    Cash at bank and in hand 54/58 €182,674 €172,593 -€10,082 -5.5%
    Deferred charges and accrued income 490/1 €0 - =
    Total equity and liabilities 10/49 €1,236,022 €1,224,794 -€11,228 -0.9%
    Equity 10/15 €1,223,097 €1,210,859 -€12,238 -1.0%
    Contributions 10/11 €1,440,000 €1,440,000 = 0.0%
    Reserves 13 €148,226 €148,226 = 0.0%
    Non-distributable reserves 130/1 €0 - =
    Reserves not available under the articles 1311 €0 - =
    Distributable reserves 133 €148,226 €148,226 = 0.0%
    Profit (loss) carried forward 14 -€365,129 -€377,367 -€12,238 -3.4%
    Amounts payable 17/49 €12,925 €13,935 +€1,010 +7.8%
    Amounts payable within one year 42/48 €11,868 €12,630 +€762 +6.4%
    Trade debts 44 €2,978 €3,409 +€431 +14.5%
    Suppliers 440/4 €2,978 €3,409 +€431 +14.5%
    Other amounts payable 47/48 €8,890 €9,221 +€331 +3.7%
    Accrued charges and deferred income 492/3 €1,057 €1,305 +€248 +23.4%
    Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €31,737 €31,737 = 0.0%
    Other operating charges 640/8 €5,068 €5,217 +€149 +2.9%
    Gross operating margin 9900 €11,928 €24,251 +€12,323 +103%
    Operating profit (loss) 9901 -€24,877 -€12,703 +€12,174 +48.9%
    Financial income 75/76B €308 €625 +€317 +103%
    Recurring financial income 75 €308 €625 +€317 +103%
    Financial charges 65/66B €73 €160 +€87 +118%
    Recurring financial charges 65 €73 €160 +€87 +118%
    Profit (loss) for the period before taxes 9903 -€24,642 -€12,238 +€12,404 +50.3%
    Profit (loss) for the period 9904 -€24,642 -€12,238 +€12,404 +50.3%
    Profit (loss) for the period to be appropriated 9905 -€24,642 -€12,238 +€12,404 +50.3%

    Value

    latest balance sheet 30-06-2025 · indication, not a valuation or advice

    Indicative value of the equity

    Indication, not a valuation or advice
    €1.2m to €1.2m

    Midpoint €1.2m · adjusted equity only

    Capitalisation rate 12% result over 3 years earnings weight 50%

    Worked out with Checked's starting values, not your estimate and not market data. Change the assumptions: the value follows.

    Adjusted equity €1.2m
    Indication €1.2m

    Adjusted equity

    balance sheet 30-06-2025
    Equity (10/15)
    €1,210,859
    Revaluation of assets
    €0
    Deferred tax on the revaluation
    €0
    Other adjustment
    €0
    Adjusted equity
    €1.2m

    Capitalised earnings

    net result for the year (9904)
    2025
    -€12,238
    2024
    -€24,642
    2023
    -€8,345
    2022
    -€25,411
    excluding non-recurring income and charges
    -€31,661
    2021
    -€32,200
    Average result
    -€15,075
    Divided by the capitalisation rate
    14% / 12% / 10%
    Capitalised earnings
    not meaningful, as the average result is zero or negative

    Limits of the indication

    • Checked holds no market prices or comparable transactions.
    • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
    • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
    • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
    • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

    For a valuation to base a decision on, go to a company auditor or a certified accountant.

    Calculation and sources

    Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 30 June 2024 and 30 June 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 16 November 2026 via checked.be.